“it’s just so important that men get tested and have conversations with their doctors to make the best decisions,” mcdonald says, adding he wants to stay well and active for his kids and eight grandchildren, and one of the most “phenomenal” jobs he’s had after retiring from playing pro sport. he’s chaired the board of the hockey hall of fame since 2015.
generally, prostate testing is recommended for men from age 50, unless you’re considered at high risk of developing prostate cancer where testing earlier is advised at age 40 to 45. black men, including those of african or caribbean ancestry, and those with a family history of prostate cancer or family history of brca2 genetic mutation (also widely known for its role in breast cancer for women and men) are considered to be at higher risk.
screening involves a prostate specific antigen (psa) test that measures the level of psa in the blood. the prostation campaign is also spreading the word about new advanced testing methods. prostate-specific membrane antigen (psma) and positron emission tomography (pet) have been developed to detect cancer progression and spread across the body.
so, if you are diagnosed with prostate cancer, these improved imaging tools will help tailor treatments to your particular case.
“psa and psma are both important biomarkers to tell us different things related to prostate cancer and prostate health,” says dr. steven yip, a frontrunner in prostate cancer research in the country. he is a medical oncologist at the tom baker cancer centre in calgary, alta. and precision oncology and experimental therapeutics lead. yip is also a clinical associate professor at the university of calgary.
“psa is the prostate specific antigen that is detected through a blood test, and it’s for individuals who have been either screened or diagnosed for prostate cancer. it also helps track the disease, and tell us the way it’s behaving, the way it might potentially be progressing,” he says. “psma, which is a prostate-specific membrane antigen, is a protein that can be present on various cells, but it is over-expressed in prostate cancer.”